CRBU Caribou Biosciences, Inc.
Healthcare$2.16+2.86%ClosedMarket Cap: $214.2M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.97
P/S
18.59
EV/EBITDA
-1.92
DCF Value
$-2.71
FCF Yield
-48.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.2%
Operating Margin
-1175.7%
Net Margin
-1189.1%
ROE
-100.1%
ROA
-89.4%
ROIC
-100.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $2.4M | 72.9% | $-26.3M | $-25.1M | $— | — |
| Q4 null | $3.9M | 100.0% | $-28.5M | $-26.5M | $— | — |
| FY null | $11.2M | 67.3% | $-136.2M | $-148.1M | $— | — |
| Q3 null | $2.2M | 100.0% | $-29.4M | $-27.5M | $— | — |
| Q2 null | $2.7M | 100.0% | $-47.6M | $-54.1M | $— | — |
| Q1 null | $2.4M | 100.0% | $-42.9M | $-40.0M | $— | — |
| Q4 null | $2.1M | -1337.8% | $-38.9M | $-35.5M | $— | — |
| FY null | $10.0M | 60.7% | $-166.6M | $-149.1M | $— | — |
| Q3 null | $2.0M | 100.0% | $-38.2M | $-34.7M | $— | — |
| Q2 null | $3.5M | 75.3% | $-43.5M | $-37.7M | $— | — |
| Q1 null | $2.4M | 70.8% | $-46.0M | $-41.2M | $— | — |
| Q4 2023 | $3.6M | 44.5% | $-37.4M | $-34.5M | $-0.39 | — |